Apoferritin as an ubiquitous nanocarrier with excellent shelf life

Simona Dostalova,1,2 Katerina Vasickova,1 David Hynek,1,2 Sona Krizkova,1,2 Lukas Richtera,1,2 Marketa Vaculovicova,1,2 Tomas Eckschlager,3 Marie Stiborova,4 Zbynek Heger,1,2 Vojtech Adam1,2 1Department of Chemistry and Biochemistry, Mendel University in Brno, 2Central European Institute of Technol...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dostalova S, Vasickova K, Hynek D, Krizkova S, Richtera L, Vaculovicova M, Eckschlager T, Stiborova M, Heger Z, Adam V
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	anticancer therapy doxorubicin-loaded apoferritin encapsulation long-term stability protein nanocarriers Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/298a996171f54374a6ce7ba35af2119b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:298a996171f54374a6ce7ba35af2119b
record_format	dspace
spelling	oai:doaj.org-article:298a996171f54374a6ce7ba35af2119b2021-12-02T07:44:03ZApoferritin as an ubiquitous nanocarrier with excellent shelf life1178-2013https://doaj.org/article/298a996171f54374a6ce7ba35af2119b2017-03-01T00:00:00Zhttps://www.dovepress.com/apoferritin-as-an-ubiquitous-nanocarrier-with-excellent-shelf-life-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Simona Dostalova,1,2 Katerina Vasickova,1 David Hynek,1,2 Sona Krizkova,1,2 Lukas Richtera,1,2 Marketa Vaculovicova,1,2 Tomas Eckschlager,3 Marie Stiborova,4 Zbynek Heger,1,2 Vojtech Adam1,2 1Department of Chemistry and Biochemistry, Mendel University in Brno, 2Central European Institute of Technology, Brno University of Technology, Brno, 3Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, University Hospital Motol, Charles University, 4Department of Biochemistry, Faculty of Science, Charles University, Prague, Czech Republic Abstract: Due to many adverse effects of conventional chemotherapy, novel methods of targeting drugs to cancer cells are being investigated. Nanosize carriers are a suitable platform for this specific delivery. Herein, we evaluated the long-term stability of the naturally found protein nanocarrier apoferritin (Apo) with encapsulated doxorubicin (Dox). The encapsulation was performed using Apo’s ability to disassemble reversibly into its subunits at low pH (2.7) and reassemble in neutral pH (7.2), physically entrapping drug molecules in its cavity (creating ApoDox). In this study, ApoDox was prepared in water and phosphate-buffered saline and stored for 12 weeks in various conditions (-20°C, 4°C, 20°C, and 37°C in dark, and 4°C and 20°C under ambient light). During storage, a very low amount of prematurely released drug molecules were detected (maximum of 7.5% for ApoDox prepared in PBS and 4.4% for ApoDox prepared in water). Fourier-transform infrared spectra revealed no significant differences in any of the samples after storage. Most of the ApoDox prepared in phosphate-buffered saline and ApoDox prepared in water and stored at -20°C formed very large aggregates (up to 487% of original size). Only ApoDox prepared in water and stored at 4°C showed no significant increase in size or shape. Although this storage caused slower internalization to LNCaP prostate cancer cells, ApoDox (2.5 µM of Dox) still retained its ability to inhibit completely the growth of 1.5×104 LNCaP cells after 72 hours. ApoDox stored at 20°C and 37°C in water was not able to deliver Dox inside the nucleus, and thus did not inhibit the growth of the LNCaP cells. Overall, our study demonstrates that ApoDox has very good stability over the course of 12 weeks when stored properly (at 4°C), and is thus suitable for use as a nanocarrier in the specific delivery of anticancer drugs to patients. Keywords: anticancer therapy, doxorubicin-loaded apoferritin, encapsulation, long-term stability, protein nanocarriersDostalova SVasickova KHynek DKrizkova SRichtera LVaculovicova MEckschlager TStiborova MHeger ZAdam VDove Medical Pressarticleanticancer therapydoxorubicin-loaded apoferritinencapsulationlong-term stabilityprotein nanocarriersMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 12, Pp 2265-2278 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	anticancer therapy doxorubicin-loaded apoferritin encapsulation long-term stability protein nanocarriers Medicine (General) R5-920
spellingShingle	anticancer therapy doxorubicin-loaded apoferritin encapsulation long-term stability protein nanocarriers Medicine (General) R5-920 Dostalova S Vasickova K Hynek D Krizkova S Richtera L Vaculovicova M Eckschlager T Stiborova M Heger Z Adam V Apoferritin as an ubiquitous nanocarrier with excellent shelf life
description	Simona Dostalova,1,2 Katerina Vasickova,1 David Hynek,1,2 Sona Krizkova,1,2 Lukas Richtera,1,2 Marketa Vaculovicova,1,2 Tomas Eckschlager,3 Marie Stiborova,4 Zbynek Heger,1,2 Vojtech Adam1,2 1Department of Chemistry and Biochemistry, Mendel University in Brno, 2Central European Institute of Technology, Brno University of Technology, Brno, 3Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, University Hospital Motol, Charles University, 4Department of Biochemistry, Faculty of Science, Charles University, Prague, Czech Republic Abstract: Due to many adverse effects of conventional chemotherapy, novel methods of targeting drugs to cancer cells are being investigated. Nanosize carriers are a suitable platform for this specific delivery. Herein, we evaluated the long-term stability of the naturally found protein nanocarrier apoferritin (Apo) with encapsulated doxorubicin (Dox). The encapsulation was performed using Apo’s ability to disassemble reversibly into its subunits at low pH (2.7) and reassemble in neutral pH (7.2), physically entrapping drug molecules in its cavity (creating ApoDox). In this study, ApoDox was prepared in water and phosphate-buffered saline and stored for 12 weeks in various conditions (-20°C, 4°C, 20°C, and 37°C in dark, and 4°C and 20°C under ambient light). During storage, a very low amount of prematurely released drug molecules were detected (maximum of 7.5% for ApoDox prepared in PBS and 4.4% for ApoDox prepared in water). Fourier-transform infrared spectra revealed no significant differences in any of the samples after storage. Most of the ApoDox prepared in phosphate-buffered saline and ApoDox prepared in water and stored at -20°C formed very large aggregates (up to 487% of original size). Only ApoDox prepared in water and stored at 4°C showed no significant increase in size or shape. Although this storage caused slower internalization to LNCaP prostate cancer cells, ApoDox (2.5 µM of Dox) still retained its ability to inhibit completely the growth of 1.5×104 LNCaP cells after 72 hours. ApoDox stored at 20°C and 37°C in water was not able to deliver Dox inside the nucleus, and thus did not inhibit the growth of the LNCaP cells. Overall, our study demonstrates that ApoDox has very good stability over the course of 12 weeks when stored properly (at 4°C), and is thus suitable for use as a nanocarrier in the specific delivery of anticancer drugs to patients. Keywords: anticancer therapy, doxorubicin-loaded apoferritin, encapsulation, long-term stability, protein nanocarriers
format	article
author	Dostalova S Vasickova K Hynek D Krizkova S Richtera L Vaculovicova M Eckschlager T Stiborova M Heger Z Adam V
author_facet	Dostalova S Vasickova K Hynek D Krizkova S Richtera L Vaculovicova M Eckschlager T Stiborova M Heger Z Adam V
author_sort	Dostalova S
title	Apoferritin as an ubiquitous nanocarrier with excellent shelf life
title_short	Apoferritin as an ubiquitous nanocarrier with excellent shelf life
title_full	Apoferritin as an ubiquitous nanocarrier with excellent shelf life
title_fullStr	Apoferritin as an ubiquitous nanocarrier with excellent shelf life
title_full_unstemmed	Apoferritin as an ubiquitous nanocarrier with excellent shelf life
title_sort	apoferritin as an ubiquitous nanocarrier with excellent shelf life
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/298a996171f54374a6ce7ba35af2119b
work_keys_str_mv	AT dostalovas apoferritinasanubiquitousnanocarrierwithexcellentshelflife AT vasickovak apoferritinasanubiquitousnanocarrierwithexcellentshelflife AT hynekd apoferritinasanubiquitousnanocarrierwithexcellentshelflife AT krizkovas apoferritinasanubiquitousnanocarrierwithexcellentshelflife AT richteral apoferritinasanubiquitousnanocarrierwithexcellentshelflife AT vaculovicovam apoferritinasanubiquitousnanocarrierwithexcellentshelflife AT eckschlagert apoferritinasanubiquitousnanocarrierwithexcellentshelflife AT stiborovam apoferritinasanubiquitousnanocarrierwithexcellentshelflife AT hegerz apoferritinasanubiquitousnanocarrierwithexcellentshelflife AT adamv apoferritinasanubiquitousnanocarrierwithexcellentshelflife
_version_	1718399208812183552

Apoferritin as an ubiquitous nanocarrier with excellent shelf life

Ejemplares similares